Skip Navigation



European Heart Journal Advance Access published online on April 19, 2006
European Heart Journal, doi:10.1093/eurheartj/ehl003
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
27/10/1251    most recent
ehl003v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Neilan, T. G.
Right arrow Articles by Fitzgerald, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neilan, T. G.
Right arrow Articles by Fitzgerald, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal © The European Society of Cardiology 2006; all rights reserved
Received July 21, 2004
Revised March 15, 2006
Accepted April 6, 2006

Preclinical research

Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression

Tomas G. Neilan 1 *, Davinder S. Jassal 2, Michael F. Scully 1, Gang Chen 3, Catherine Deflandre 4, Hester McAllister 4, Elaine Kay 5, Sandra C. Austin 1, Elkan F. Halpern 6, Judy H. Harmey 3, and Desmond J. Fitzgerald 1

1 Department of Clinical Pharmacology, Institute of Biopharmaceutical Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
2 Cardiac Ultrasound Laboratory, Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, USA
3 Department of Surgery, Beaumont Hospital, Dublin, Ireland
4 Department of Veterinary Medicine, University College Dublin, Ireland
5 Department of Pathology, Beaumont Hospital, Dublin, Ireland
6 The Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA

* To whom correspondence should be addressed.
Tomas G. Neilan, E-mail: tneilan{at}partners.org


  Abstract

Aims The use of doxorubicin (DOX) as a chemotherapeutic agent is limited by cardiac injury. Iloprost, a stable synthetic analogue of prostacyclin, has previously been shown to protect against DOX-induced cardiomyocyte injury in vitro. Here, we addressed whether iloprost is cardioprotective in vivo and whether it compromises the anti-tumour efficacy of DOX.

Methods and results Lewis Lung Carcinoma cells were implanted subcutaneously in the flank of C57BL/6 mice. DOX treatment was commenced from when tumours became visible. Iloprost was administered from prior to DOX treatment until sacrifice. Echocardiography and invasive haemodynamic measurements were performed immediately before sacrifice. As expected, DOX induced cardiac cell apoptosis and cardiac dysfunction, both of which were attenuated by iloprost. Also, iloprost alone had no effect on tumor growth and indeed, did not alter the DOX-induced suppression of this growth.

Conclusion In a murine model, iloprost attenuated the acute cardiac injury and dysfunction induced by DOX therapy without compromising its chemotherapeutic effect.

Keywords: Doxorubicin; Cardiotoxicity; Cyclooxygenase; Prostaglandins.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
C. B. Granger
Prediction and Prevention of Chemotherapy-Induced Cardiomyopathy: Can It Be Done?
Circulation, December 5, 2006; 114(23): 2432 - 2433.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Y. Kuramochi, H. Takagi, and T. Morita
Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumor suppression
Eur. Heart J., November 1, 2006; 27(21): 2610 - 2611.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
P. G. Horan, M. F. McMullin, and P. P. McKeown
Anthracycline cardiotoxicity
Eur. Heart J., May 2, 2006; 27(10): 1137 - 1138.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.